CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Adult
Aged
Apoptosis
/ drug effects
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cyclin-Dependent Kinase 4
/ antagonists & inhibitors
Cyclin-Dependent Kinase 6
/ antagonists & inhibitors
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
/ genetics
Drug Synergism
Female
Fusion Proteins, bcr-abl
/ genetics
Humans
Hydroxyurea
/ pharmacology
Imidazoles
/ pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ genetics
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ pharmacology
Pyridazines
/ pharmacology
BCR-ABL1 mutations
CDK4/CDK6 – Palbociclib
CML
Hydroxyurea
TKI resistance
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
08
08
2019
revised:
28
10
2019
accepted:
05
11
2019
pubmed:
26
11
2019
medline:
1
5
2020
entrez:
26
11
2019
Statut:
ppublish
Résumé
Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1 Viability, apoptosis and proliferation of drug-exposed primary CML cells and BCR-ABL1+ cell lines were examined by flow cytometry and HU was more effective in inhibiting the proliferation of leukemic cells harboring BCR-ABL1 HU and the CDK4/CDK6-blocker palbociclib inhibit growth of CML clones expressing BCR-ABL1 This project was supported by the Austrian Science Funds (FWF) projects F4701-B20, F4704-B20 and P30625.
Identifiants
pubmed: 31761618
pii: S2352-3964(19)30745-5
doi: 10.1016/j.ebiom.2019.11.004
pmc: PMC6921367
pii:
doi:
Substances chimiques
BCR-ABL1 fusion protein, human
0
Imidazoles
0
Protein Kinase Inhibitors
0
Pyridazines
0
ponatinib
4340891KFS
Fusion Proteins, bcr-abl
EC 2.7.10.2
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Hydroxyurea
X6Q56QN5QC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-121Subventions
Organisme : Austrian Science Fund FWF
ID : P 30625
Pays : Austria
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Leukemia. 2003 Aug;17(8):1529-37
pubmed: 12886239
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Leukemia. 2007 Oct;21(10):2204-6
pubmed: 17541396
Nature. 2017 Mar 30;543(7647):733-737
pubmed: 28329763
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Cancer Res. 2006 Aug 1;66(15):7661-7
pubmed: 16885367
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5
pubmed: 24550512
Oncotarget. 2017 Jun 28;8(40):67709-67722
pubmed: 28978065
Br J Haematol. 2019 Oct;187(1):e15-e17
pubmed: 31368155
Blood. 1993 Jul 15;82(2):398-407
pubmed: 8329700
Blood. 2007 Oct 1;110(7):2779-80
pubmed: 17881650
Hematol Oncol. 2018 Oct;36(4):718-720
pubmed: 29901221
Blood. 2013 Jan 17;121(3):489-98
pubmed: 23223358
Cancer. 2017 Aug 1;123(15):2875-2880
pubmed: 28387926
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Clin Cancer Res. 2008 Jul 15;14(14):4392-9
pubmed: 18628453
Leukemia. 2015 Sep;29(9):1823-31
pubmed: 26088952
Cancer Res. 2002 Dec 15;62(24):7149-53
pubmed: 12499247
J Biol Chem. 2010 Feb 12;285(7):5085-96
pubmed: 20007699
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):515-29
pubmed: 23890944
Genes (Basel). 2016 Nov 17;7(11):
pubmed: 27869662
Semin Oncol. 1992 Jun;19(3 Suppl 9):21-6
pubmed: 1641653
Biol Blood Marrow Transplant. 2016 Jun;22(6):1080-1086
pubmed: 26995693
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Clin Drug Investig. 2018 May;38(5):475-476
pubmed: 29363026
Blood. 2015 Feb 5;125(6):901-6
pubmed: 25525119
Leukemia. 2008 Oct;22(10):1956-61
pubmed: 18432261
J Clin Oncol. 2009 Dec 10;27(35):6041-51
pubmed: 19884523
Blood. 2014 Dec 18;124(26):3850-7; quiz 4004
pubmed: 25287707
J Clin Oncol. 2014 Feb 10;32(5):415-23
pubmed: 24297946
Oncotarget. 2016 Nov 22;7(47):78083-78094
pubmed: 27801667
Brain Res. 2008 Jan 10;1188:25-34
pubmed: 18048012
Blood. 2009 Dec 24;114(27):5426-35
pubmed: 19880502
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612
pubmed: 28673390
Haematologica. 2011 Mar;96(3):360-6
pubmed: 21134983
Leuk Lymphoma. 2002 Jun;43(6):1289-95
pubmed: 12152998
Mol Cancer Ther. 2016 Jan;15(1):94-105
pubmed: 26637365
Ann Hematol. 2009 Jul;88(7):629-32
pubmed: 19096846
Leukemia. 2015 May;29(5):1104-14
pubmed: 25394714
Haematologica. 2018 Jan;103(1):e10-e12
pubmed: 28983061
Blood. 2011 Aug 4;118(5):1208-15
pubmed: 21562040
Semin Hematol. 2007 Jan;44(1 Suppl 1):S15-24
pubmed: 17292737
Mol Cell Biol. 2006 Aug;26(16):6082-93
pubmed: 16880519
Blood. 2015 Jan 1;125(1):90-101
pubmed: 25342715
Drug Discov Today Technol. 2014 Mar;11:89-99
pubmed: 24847658
Leuk Res. 1988;12(6):453-8
pubmed: 3165485
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Front Cell Dev Biol. 2015 Apr 09;3:16
pubmed: 25914884
Lancet Haematol. 2015 Sep;2(9):e376-83
pubmed: 26436130
Leukemia. 2009 Nov;23(11):1957-63
pubmed: 19710700
Nat Rev Clin Oncol. 2016 Feb;13(2):79-91
pubmed: 26573423
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Cancer Res. 2010 Feb 15;70(4):1513-23
pubmed: 20145140
Mutat Res. 1975;32(2):115-32
pubmed: 765790
Cell Growth Differ. 2001 Sep;12(9):481-6
pubmed: 11571231
Leukemia. 2014 Apr;28(4):976-7
pubmed: 24170029
Nat Rev Cancer. 2008 May;8(5):341-50
pubmed: 18385684